Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 16Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myeloid, Acute 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Uterine Cervical Neoplasms 1Solid Tumors Refractory to Standard Therapy 1Solid Tumors 1Solid Tumor, Adult 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Liposarcoma, Myxoid 1Liposarcoma 1Kidney Neoplasms 1Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1Glioblastoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1ER+ HER2- Advanced Breast Cancer 1

Interventions

selinexor 1seclidemstat 1pazopanib 1palbociclib 1mirdametinib 1Trabectedin 1Topotecan 1Radiotherapy 1Proton Therapy 1Ifosfamide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Liposarcoma, Myxoid × palbociclib × Clear all
NCT06843967 2026-05-22

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Recruiting
54 enrolled
Sarcoma

Liposarcoma, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡